REILAND WAKEMAN, Joanne,ROWLINGS, Colin,LIU, Sha,BURKE, Gerry,VON CORSWANT, Christian,TANNERGREN, Christer,HJARTSTAM, Johan
申请号：
PE2018001088
公开号：
PE20181521A1
申请日:
2016.12.07
申请国别(地区):
PE
年份:
2018
代理人:
摘要：
This is a modified release pharmaceutical compound containing 2 - ((3 - (4-cyano-o-1-il) pyridine-4-il) tert butyl-2-methylpropane (referred to as the "preparation"), which contains an xantina oxidase inhibitor called febxostat, After fasting and oral administration to one subject, the maximum plasma concentration was produced, between 1 and 50 ng / ml, a Cmax / auc0-24 ratio of 0.04-0.4, etc.； in this case, the dose of the agent was between 0.5-20 mg. This drug synthesis is an effective method for the treatment of uric acid metabolic disorders, including polypeptides, metabolic poliomyelitis, gout,Among other thingsSe refiere a composiciones farmaceuticas que contienen acido 2-(( 3-( 4-cianonaftalen-1-il) piridin-4-il)tio )-2-metilpropanoico (denominado ¨Agente¨) de liberacion modificada, donde dicha composicion comprende un inhibidor de xantina oxidasa llamada febuxostat, despues de la administracion oral en ayunas a un sujeto produce una concentracion plasmatica maxima media geometrica (Cmax) del agente entre 1 ng/mL y 50 ng/mL, una relacion de Cmax/AUC0-24 entre 0,04 y 0,4, entre otros； donde la dosis del agente varia entre 0,5-20 mg. Dicha composicion farmaceutica es util para tratar trastornos del metabolismo del acido urico que incluyen policitemia, metaplasia mieliode, gota , entre otros
